ZA201109199B - Recombinant rsv antigens - Google Patents

Recombinant rsv antigens

Info

Publication number
ZA201109199B
ZA201109199B ZA2011/09199A ZA201109199A ZA201109199B ZA 201109199 B ZA201109199 B ZA 201109199B ZA 2011/09199 A ZA2011/09199 A ZA 2011/09199A ZA 201109199 A ZA201109199 A ZA 201109199A ZA 201109199 B ZA201109199 B ZA 201109199B
Authority
ZA
South Africa
Prior art keywords
recombinant rsv
rsv antigens
antigens
recombinant
rsv
Prior art date
Application number
ZA2011/09199A
Other languages
English (en)
Inventor
Guy Jean Marie Fernand Pierre Baudoux
Normand Blais
Sonya L Cyr
Patrick Rheault
Jean Louis Ruelle
Original Assignee
Glaxosmithkline Biologicals Sa
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42670494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201109199(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa, Id Biomedical Corp Quebec filed Critical Glaxosmithkline Biologicals Sa
Publication of ZA201109199B publication Critical patent/ZA201109199B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2011/09199A 2009-06-24 2011-12-14 Recombinant rsv antigens ZA201109199B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21996409P 2009-06-24 2009-06-24
US33456810P 2010-05-13 2010-05-13
PCT/EP2010/059008 WO2010149745A1 (en) 2009-06-24 2010-06-24 Recombinant rsv antigens

Publications (1)

Publication Number Publication Date
ZA201109199B true ZA201109199B (en) 2012-08-29

Family

ID=42670494

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/09199A ZA201109199B (en) 2009-06-24 2011-12-14 Recombinant rsv antigens

Country Status (29)

Country Link
US (1) US9492531B2 (cg-RX-API-DMAC7.html)
EP (1) EP2445526B1 (cg-RX-API-DMAC7.html)
JP (2) JP6062245B2 (cg-RX-API-DMAC7.html)
KR (1) KR101696002B1 (cg-RX-API-DMAC7.html)
CN (1) CN102481359B (cg-RX-API-DMAC7.html)
AU (2) AU2010264688A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1015917A2 (cg-RX-API-DMAC7.html)
CA (1) CA2766211A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011003273A1 (cg-RX-API-DMAC7.html)
CO (1) CO6480978A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120025A (cg-RX-API-DMAC7.html)
CY (1) CY1117673T1 (cg-RX-API-DMAC7.html)
DK (1) DK2445526T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000389A (cg-RX-API-DMAC7.html)
EA (1) EA023054B1 (cg-RX-API-DMAC7.html)
ES (1) ES2583257T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160798T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028085T2 (cg-RX-API-DMAC7.html)
IL (1) IL217013B (cg-RX-API-DMAC7.html)
MA (1) MA33449B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012000035A (cg-RX-API-DMAC7.html)
PE (1) PE20121541A1 (cg-RX-API-DMAC7.html)
PL (1) PL2445526T3 (cg-RX-API-DMAC7.html)
PT (1) PT2445526T (cg-RX-API-DMAC7.html)
SG (1) SG176829A1 (cg-RX-API-DMAC7.html)
SI (1) SI2445526T1 (cg-RX-API-DMAC7.html)
UA (1) UA111141C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010149745A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201109199B (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4206231A1 (en) 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
EP3718566B1 (en) * 2008-12-09 2024-06-12 Novavax, Inc. Modified rsv f proteins and methods of their use
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
CN102639147B (zh) 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
SG194755A1 (en) * 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
CN102294027A (zh) * 2011-07-26 2011-12-28 昆明理工大学 一种呼吸道合胞病毒f2蛋白亚单位疫苗及其制备方法
JP6085886B2 (ja) 2011-08-29 2017-03-01 国立大学法人徳島大学 Ｒｓｖ粘膜ワクチン
DK3311827T3 (da) * 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
CN102743750B (zh) * 2012-07-09 2013-11-20 江苏省农业科学院 一种复方免疫增强剂、禽用疫苗及其制备方法
EP3656396A1 (en) 2012-08-01 2020-05-27 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
US20140037680A1 (en) * 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
CN103204943B (zh) * 2013-03-20 2014-07-23 中国科学院武汉病毒研究所 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途
WO2014168821A1 (en) * 2013-04-08 2014-10-16 Medimmune, Llc Vaccine composition and method of use
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3030260A1 (en) * 2013-08-05 2016-06-15 GlaxoSmithKline Biologicals S.A. Combination immunogenic compositions
US9388430B2 (en) * 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
JP6664338B2 (ja) * 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
AU2016289492B2 (en) 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN115442571A (zh) * 2016-09-23 2022-12-06 伊姆西Ip控股有限责任公司 用于视频监控系统的故障恢复方法和装置
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組ｒｓｖ抗原
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
RU2019142012A (ru) 2017-06-14 2021-07-14 Вирометикс Аг Циклические пептиды для защиты от респираторно-синцитиального вируса
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
KR102700187B1 (ko) * 2017-09-29 2024-08-28 에스케이바이오사이언스(주) 가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
EP4227319B1 (en) * 2018-04-17 2025-11-26 CureVac SE Novel rsv rna molecules and compositions for vaccination
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
CN113260377B (zh) 2018-12-20 2025-08-22 维罗米蒂克斯股份公司 脂肽构建块和合成病毒样颗粒
KR102679227B1 (ko) * 2019-02-28 2024-06-28 케이엠 바이올로직스 가부시키가이샤 Rsv f/g 키메라 백신
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN114685627A (zh) * 2020-12-28 2022-07-01 广州更新生物医药科技有限公司 一种预防呼吸道合胞病毒的rAAV载体疫苗
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
CN115772230A (zh) * 2022-07-18 2023-03-10 青岛硕景生物科技有限公司 一种rsv重组抗原、其制备方法及应用
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
TWI888970B (zh) 2022-10-27 2025-07-01 美商輝瑞大藥廠 Rna分子
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv
AU2024209772A1 (en) 2023-01-18 2025-06-26 Pfizer Inc. Vaccines against respiratory diseases
CN118078975A (zh) * 2023-03-17 2024-05-28 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
TW202515531A (zh) 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性ｔｌｒ７／８佐劑及其用途
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
ATE85622T1 (de) 1987-12-23 1993-02-15 Upjohn Co Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0678102A1 (en) 1993-01-08 1995-10-25 The Upjohn Company Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
CN1055093C (zh) 1993-11-17 2000-08-02 实验室奥姆公司 葡糖胺二糖类、其制备方法和用途、以及含有这些二糖的药物组合物
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
DE69828801T2 (de) 1997-09-19 2005-07-14 Wyeth Holdings Corp. Peptide, abgeleitet vom angelagerten g-protein des respiratory syncytial virus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
SK18602000A3 (sk) 1998-06-08 2001-07-10 Sca Emballage France Obal umožňujúci rýchle vyrovnanie
ATE355266T1 (de) 1998-06-30 2006-03-15 Om Pharma Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
AU2002223275A1 (en) * 2000-11-22 2002-06-03 Biota Scientific Management Pty Ltd A method of expression and agents identified thereby
ES2330201T3 (es) 2001-01-26 2009-12-07 Selexis S.A. Regiones de union a la matriz y metodos para el uso de las mismas.
MXPA03008154A (es) 2001-03-09 2004-11-12 Id Biomedical Corp Quebec Novedoso adyuvante de vacuna de proteosoma-liposacarido.
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
EP1592302A4 (en) 2003-02-13 2007-04-25 3M Innovative Properties Co METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
SG147468A1 (en) 2003-10-24 2008-11-28 Selexis Sa High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
FR2873378A1 (fr) 2004-07-23 2006-01-27 Pierre Fabre Medicament Sa Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques
GB0422439D0 (en) 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20080233150A1 (en) * 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
US20100203071A1 (en) 2007-03-21 2010-08-12 Norman Blais Chimeric antigens
US20100261155A1 (en) 2007-06-06 2010-10-14 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
EP4206231A1 (en) 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
EP2324062A4 (en) 2008-07-18 2012-06-06 Id Biomedical Corp Quebec CHIMERIC RSV POLYPEPTIDE ANTIGEN
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine

Also Published As

Publication number Publication date
IL217013B (en) 2018-02-28
CN102481359B (zh) 2015-08-19
JP6062245B2 (ja) 2017-01-18
EP2445526B1 (en) 2016-05-11
AU2014203636C1 (en) 2017-02-09
DOP2011000389A (es) 2012-04-30
EA023054B1 (ru) 2016-04-29
AU2010264688A1 (en) 2012-01-19
PE20121541A1 (es) 2012-12-21
KR101696002B1 (ko) 2017-01-13
CR20120025A (es) 2012-05-28
PL2445526T3 (pl) 2017-08-31
SG176829A1 (en) 2012-01-30
WO2010149745A1 (en) 2010-12-29
MA33449B1 (fr) 2012-07-03
US20120093847A1 (en) 2012-04-19
ES2583257T3 (es) 2016-09-20
HUE028085T2 (en) 2016-11-28
CO6480978A2 (es) 2012-07-16
MX2012000035A (es) 2012-02-28
DK2445526T3 (en) 2016-06-27
US9492531B2 (en) 2016-11-15
CL2011003273A1 (es) 2012-10-19
IL217013A0 (en) 2012-02-29
UA111141C2 (uk) 2016-04-11
SI2445526T1 (sl) 2016-08-31
BRPI1015917A2 (pt) 2019-08-27
JP2012530504A (ja) 2012-12-06
EP2445526A1 (en) 2012-05-02
JP2016128457A (ja) 2016-07-14
EA201270063A1 (ru) 2012-07-30
PT2445526T (pt) 2016-08-16
CY1117673T1 (el) 2017-05-17
AU2014203636A1 (en) 2014-07-31
AU2014203636B2 (en) 2016-10-20
HRP20160798T1 (hr) 2016-08-12
KR20120097472A (ko) 2012-09-04
CN102481359A (zh) 2012-05-30
CA2766211A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
IL217013A0 (en) Recombinant rsv antigens
ZA201004289B (en) Recombinant rsv antigens
EP2409990A4 (en) VARIANT OF A CONSTANT ANTIBODY REGION
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
SG10201401331TA (en) Anti-siglec-15 antibody
IL218858A0 (en) Albumin variants
PT2294202E (pt) Antigénios gripais recombinantes solúveis
IL216097A0 (en) Anti-axl antibody
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
HRP20141257T1 (en) Antibodies against her2 truncated variant ctf-611
GB0920324D0 (en) Antibodies
GB0905972D0 (en) Antibodies against IL-17BR
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
ZA201108446B (en) FViII-DERIVED PEPTIDES
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
IL219948A0 (en) Polypeptide conjugate
ZA201203722B (en) Peptide
GB2473934B (en) Anti-VEEV antibody
GB0914046D0 (en) Bonding arrangement
GB0917685D0 (en) Antigenic polypeptide
HK1163543A (en) Recombinant rsv antigens
GB0908945D0 (en) Antibodies
GB0911712D0 (en) Antibody